

REPORT TO THE TRUST BOARD (PUBLIC)

REPORT TITLE	Cancer report
AUTHOR	Joanne Dale, Programme Director Elective Care
EXECUTIVE SPONSOR	Phil Walmsley, Chief Operating Officer
DATE OF MEETING	June 2022
PRESENTED FOR	Information
ITEM PREVIOUSLY CONSIDERED BY	Elective Care Group

Presented For: Definitions

Information	For information only. Not to be discussed at meeting unless members have specific questions.
Discussion	For discussion and possibly future decision. This includes items presented for assurance.
Decision	For approval and/or when any other decision is required

PURPOSE OF THE REPORT

The Cancer report summarises the current performance with tumour site detail, challenges and actions, and increased referrals for patients on a suspected cancer pathway. The immediate focus over the last 6 weeks has been to improve patients waiting for over 104 days with a reduction from 150 to 89 to date. Revised trajectories are also included.

The immediate actions included in the report include pathway review by tumour site, focus on the referral and triaging process supported by a task and finish group, and possible electronic solutions.

Delivery of the Cancer performance standards remain a key risk to the Trust. Cancer performance and other aspects of Elective Care delivery form the agenda of the weekly Elective Care Group. This provides a rhythm to review and manage actions within and across all divisions.

The Elective Care Group reports to the Operational Management Group, which in turn reports to the Hospital Management Group. The revised terms of reference for governance of the elective care agenda is being developed with the Director of Corporate Affairs and will be presented to the next Hospital Management Group.

The Board is asked to receive the report for information, note the challenge and progress to date in 2022/23 and future planned actions.

A comprehensive action plan captures the required specialty and department action plans.

RISKS RELEVANT TO THE PAPER

Risk ID	Risk Description

RISK APPETITE RELEVANT TO THE PAPER (insert relevant section from Risk Appetite Statement from Risk Management Policy)

DOMAIN	TRUST RISK APPETITE LEVEL	DESCRIPTION OF RISK APPETITE
Financial/ Value for Money (VfM)	Open - Willing to consider all potential delivery options and choose while also providing an acceptable level of reward (and VfM)	Prepared to invest for return and minimise the possibility of financial loss by managing the risks to a tolerable level. Value and benefits considered (not just cheapest price). Resources allocated in order to capitalise on opportunities.

THE BOARD IS ASKED TO:

1. Receive the report for information.

STRATEGIC GOALS THIS REPORT SUPPORTS (Check all that apply)

Delivering outstanding care and experience	<input checked="" type="checkbox"/>
Recruiting developing and retaining our workforce	<input type="checkbox"/>
Improving and developing our services and infrastructure	<input checked="" type="checkbox"/>
Working together with local health and social care providers	<input type="checkbox"/>
Delivering financial sustainability	<input type="checkbox"/>

OTHER IMPLICATIONS OF THE PAPER

Legal/ Regulatory Relevance:	National access standards for patients referred on a suspected cancer pathway
NHS Constitution Delivery	Access standards
Freedom of Information Release	This report cannot be released under the Freedom of information Act 2000

Equality and Diversity Implications (Check all that apply)

Age	Gender	Ethnicity	Disability	Pregnancy/ Maternity	Marriage/ Civil Partnership	Religion/ Belief	Sexual Orientation	Gender Reassignment
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Additional comments								

1. EXECUTIVE SUMMARY

The attached Cancer report summarises the current performance position with tumour site detail, challenges and actions.

Key data is included to demonstrate the increased referrals received for patients on a suspected cancer pathway.

The long waiting patient numbers are included which is an initial focus on delivering an improved position and a key concern of regulators and commissioners. The improving position during 2022/23 to date for this patient cohort is shown.

A comprehensive action plan captures the required specialty and department action plans. This has not been included with this report. It is monitored within the weekly meetings with tumour site teams.

The cancer agenda is overseen through the weekly Elective Care Group to provide focus, rhythm, and fast pace to addressing our pathway challenges across and between divisions.

The Board is asked to receive the report for information, note the challenge and progress to date in 2022/23 and future planned actions.